Cross-agency comparison: 🇪🇺 EMA leads with 89 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

The EMA’s much higher output over the past 90 days may indicate the most active and procedurally dynamic environment among the four, with FDA activity appearing comparatively lighter and MHRA and Health Canada sitting in a secondary tier. Sponsors should consider that this kind of spread could suggest Europe as the most change-sensitive market for near-term filing planning, while the U.S. may require less volume-driven monitoring but still demands division-specific attention. For global filing strategy, this pattern could suggest prioritizing regulatory intelligence and submission readiness resources toward the EU first, then calibrating U.S., UK, and Canadian workstreams around a more moderate update cadence. Companies planning parallel launches may want to assume that the highest workload is not necessarily the largest market, but the jurisdiction with the densest stream of guidance and procedural signals.